thumbnail image
  • Welcome
  • About Us
  • Solutions
  • Big Media
  • Button
  • Product
  • Partners
  • Team
  • Team
  • Team
  • Hero
  • Blog
  • Media
  • Press Release
  • Careers
  • Sign Up
  • Contact Us
  • FindUs
  • FR
  • Follow Us
  • About Us

    At My Intelligent Machines, we are helping life scientists harness the power of human and artificial intelligence to push the boundaries of drug development.

     

    Seventy percent of phase II and III clinical trials fail because patients with the same disease respond differently to treatments. This costs the biopharma industry more than $20B in losses annually. The cost of human life is even greater.

     

    MIMs is a software-as-a-service (SaaS) company with an augmented-intelligence platform leveraging systems biology, distributed computing, and machine learning to unleash the power of reverse translational research. We are changing the research paradigm for endotype characterization, target and indication prioritization, and target and biomarker discovery, in oncology, immune-related disorders, infectious diseases, and more.

     

    MIMs’ transformational software solutions are made possible by an inclusive team of remarkable and diverse humans – leaders of today and tomorrow in their respective fields. Together, we have brought a machine to life. Our love of science knows no bounds. Our plans are daring. Our future goals are lofty.

  • Ask for a Demo
  • Our Product

    Reduce costs, time, and failure rates associated with your clinical trials

    MIMs' Platform

    MIMs’ platform integrates our MIMsight Knowledge Base—which combines billions of data points and other information extracted from scientific literature, public databases, and multi-omic and clinical patient data-and our proprietary GI2 (Genetic Interaction Graph Inference) algorithm inferring genetic interactions within patient tumours and immune systems. These vivid human cartographies of individual patients deliver previously unimagined levels of precise insight used to classify patients into subgroups, identify their molecular and clinical characteristics, predict their response to new therapies, and identify powerful therapeutic targets and biomarkers.

     

    With MIMs’ SaaS product for indication prioritization and biomarker discovery in oncology, you and your team can:

    1. Access scientific insights to support strategic decisions on indication prioritization at the pre-clinical stage

    2. Increase the success rate of clinical trials for new targeted and immune therapies
    3. Explore new potent combined therapies

    4. Accelerate early high-value biomarkers to accelerate companion test development

  • Team

    Our co-founders combine 50 years of cumulated experience in Integrative Genomics, Bioinformatics and Artificial Intelligence

    Sarah Jenna

    Sarah Jenna

    Cofounder & CEO

    Sarah obtained her Ph.D. degree in cell biology and microbiology in University Aix-Marseille in France in 1998 and a Junior Canadian research Chair in Integrative Genomics and Cell signaling at UQAM in 2006 (The IGCS Lab). As the co-founder and CEO of MIMs Inc., she translates this expertise to provide MIMs with state-of-the-art integrative genomics abilities and attention to specific needs of biologist users.

    Mickaël Camus

    Mickaël Camus

    Cofounder & CTO

    Since 2001, Mickaël worked on various industrial projects concerning autonomous systems and unsupervised learning like a mission management System for uninhabited air vehicles for the european defence and an autonomous satellite constellation simulator for the european space agency concerning the Galileo project. During his Ph.D. Thesis from 2003 to 2007 at LIP6 from P6 & CNRS, Mickaël developed a system based on an ontology of making self-assessment decisions, that allows to generate models in real-time thanks to a massive multi-agent system. This discovery is as a master algorithm to control machines at a knowledge level (A. Newell). www.mickaelcamus.net

    Abdoulaye Baniré Diallo

    Abdoulaye Baniré Diallo

    Cofounder & CSO

    Abdoulaye is fascinated by the usability and efficiency of bioinformatics services to solve biological questions and transform biologist main needs into accessible services. As director of the bioinfo lab at UQAM, he leads the development of more than 10 applications in bioinformatics including workflows, machine learning methods, ontologies and knowledge management of biological data. Abdoulaye has a Ph.D. in computer science (option bioinformatics) from the McGill University. He is a former research associate at the BroadInstitute of MIT and Harvard and postdoctoral scholar at the Computer Science and artificial intelligence Laboratory of MIT.

  • Meet the team

    MIMs is a dynamic tech company with an exceptional culture that embraces diversity and inclusion. We are currently one of the very few tech companies to have reached gender balance

  • MIMs in the News

    Stay tuned!

  • Press Releases & White papers

  • Careers

    Join a dynamic and diverse team. Send us your resume at [email protected]

  • My Intelligent Machines

    Sign up to receive our newsletters!

  • Contact Us

© 2016 - 2022

Terms & Conditions
Privacy Policy
    Find Us
    Contact
All Posts
×
×
Terms & Conditions
TERMS OF USE - MIMS.AI
Version 1.0 posted and effective as of 8 May 2018
THESE TERMS OF USE (OR “TERMS” FOR SHORT) ARE A LEGAL CONTRACT BETWEEN YOU (OR YOUR ORGANIZATION) AND 9813063 CANADA INC. (“we”, “us” or “our”), THEY GOVERN YOUR ACCESS TO AND USE OF  OUR WEBSITE: www.mims.ai (“Website”),
PLEASE READ CAREFULLY, SINCE THESE TERMS INCLUDE LIMITATIONS OF LIABILITY AS WELL AS DISCLAIMERS OF WARRANTIES, AND OTHER TERMS WHICH AFFECT YOUR LEGAL RIGHTS. IF YOU DO NOT AGREE WITH THESE TERMS, OR IF YOU LACK CAPACITY OR AUTHORITY TO AGREE TO THESE TERMS, YOU MUST NOT VISIT OUR WEBSITE.

1. Scope of these Terms
These Terms do not apply to third-party websites, even if those websites are referenced or linked to by us or our Website. We cannot be responsible for the content of third-party websites, their terms of use, or any issues arising from your access to and use of third-party websites.

2. Changes to these Terms
We may amend any part of these Terms by adding, deleting, or varying their content. These amendments may be made at any time and from time-to-time in our discretion, and could occur very close together, or very far apart, depending on the circumstances. 
Changes will be made by updating the webpage that displays these terms and increasing the version number at the start of these terms. If you disagree with an amendment to these terms, you must cease visiting our website.

3. Authorized Activities
Subject to your compliance with these Terms, and for as long as we makes the Website available, we grant you a limited right to access the Website. 
This right takes the form of a licence that is personal, revocable, non-exclusive, non-transferrable, and non-sublicenceable. For greater certainty, this does not include any right to directly access the software, databases, algorithms or data which powers the Website, nor any right to obtain a copy of the source code or architecture thereof.
This licence authorizes limited and temporary reproduction of the Website only to the extent necessary for normal browsing activities. You may not permanently reproduce this Website or any part thereof, including any content hosted on the Website. Nor may you distribute or exploit the Website or any of its content in any manner whatsoever.
For greater certainty, nothing in these Terms provides you with any ownership interest in the intellectual property embodied in the Website or its contents. You acknowledge that intellectual property in the Website and its content belongs to us or our licensors (as the case may be), and that you shall not own same.

4. Unauthorized Activities
Consistent with the limited nature of your right to access the Website, you must not: (i) decompile, disassemble, reverse engineer, investigate, or otherwise access any non-UI portion of the Website; (ii) circumvent any limitations we place on your use of the Website; (iii) use or display the Website in such a way that this allows derivation of information about it that was not intended to be made available to users; (iv) circumvent any security features or technological protection measures built into the Website; (v) automate access to the Website, including, without limitation, through the use of APIs, bots, scrapers or other similar devices; (vi) attempt to install the Website blocked or banned by us; (vi) engage in any behaviour which has specifically been prohibited in a communication received by you from us.

5. Disclaimer of Warranties and Limitation of Liability
WE HEREBY EXCLUDE ALL REPRESENTATIONS, CONDITIONS AND WARRANTIES REGARDING THE WEBSITE AND ITS CONTENTS, WHETHER EXPRESS OR IMPLIED, INCLUDING ANY CONDITION OR WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
NOTABLY, AND WITHOUT LIMITING THE GENERALITY OF THE PRECEDING PARAGRAPH, WE NOT GUARANTEE ANY PARTICULAR LEVEL OF UP-TIME OR AVAILABILITY OF THE WEBSITE. THE WEBSITE MAY BECOME UNAVAILABLE FOR MANY REASONS, INCLUDING SCHEDULED AND UNSCHEDULED MAINTENANCE BY US. NOR DO WE PROVIDE ANY REPRESENTATION, CONDITION, OR WARRANTY REGARDING THE INFORMATION FOUND ON THIS WEBSITE, INCLUDING ANY GUARANTEE REGARDING THE ACCURACY OR RELIABILITY THEREOF. YOU HEREBY DISCLAIM ANY RIGHT TO RELY ON INFORMATION APPEARING ON THE WEBSITE.
WITH THE EXCEPTION OF INTENTIONAL WRONGDOING OR GROSS NEGLIGENCE, WE SHALL NOT BE LIABLE FOR ANY DAMAGES CAUSED BY OR RELATED TO THE WEBSITE, INFORMATION APPEARING ON IT, OUR ACTIONS OR INACTIONS, OR THESE TERMS (INCLUDING THE BREACH OF THESE TERMS). THIS LIMITATION OF LIABILITY SHALL APPLY TO ALL DAMAGES HOWEVER CAUSED, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), PROPERTY, PRIVACY, STATUTE, OR OTHERWISE. 
NOTABLY, AND WITHOUT LIMITING THE GENERALITY OF THE PRECEDING PARAGRAPH, WE SHALL NOT BE LIABLE FOR ANY LOSS OF DATA, LOSS OF REVENUE, LOSS OF PROFITS, LOSS OF BUSINESS OPPORTUNITIES, LOST TIME, OR LEGAL FEES AND LITIGATION EXPENSES.

6. General
a)    Governing law and jurisdiction
These Terms are governed exclusively by the domestic laws of Ontario and the federal laws of Canada applicable therein. The International Sale of Goods Act, RSO 1990, c I.10, does not apply to these Terms.  Any litigation between you and us arising from or related to these Terms or the Website shall be submitted to the exclusive jurisdiction of the courts of Ontario.

b)    Assignment
You may not assign any of your rights arising under these Terms without our written consent. 

c)    Status of the Parties
These Terms do not create any relationship of employment, partnership, agency, trust, franchise, or joint venture. Nor do they create any fiduciary duties.

d)    Amendments
These Terms can only be amended or suspended by following the procedure set out in clause 1, above. No other amendment or suspension is valid, nor can any purported waiver be set up against us unless the waiver follows the procedure for an amendment set out in clause 1.

e)    Entire Agreement
These Terms (as amended from time to time) constitute the entire agreement between you and us regarding the Website. These Terms (and any amendments) replace and supersede any previous or existing agreement, contract, understanding, or representation regarding the Website.

f)    Language
You and us have agreed that these Terms and all related documents be drawn up in the English language.  Les parties aux présentes reconnaissent avoir convenu que la présente entente et les documents connexes soient rédigés en langue Anglais.

g)    Privacy
We take privacy seriously. For more information on how we collect, use, and disclose personal information, please see our privacy policy, accessible here: http://www.mims.ai?open=privacy-policy

h)    Contact
General inquiries to us may be sent to the following address:
9813063 CANADA INC.
My Intelligent Machines - MIMs
51 Sherbrooke street West, office 101, Montreal, QC,
CANADA, H2X 1X2
[email protected]
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More